Novartis strengthens executive committee further
Novartis this week announced changes to its senior leadership team to support the implementation of its strategic priorities. These changes include the appointment of Shannon Klinger in the elevated and expanded role of chief ethics, risk, and compliance officer, effective April 1.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleNovartis to pay $347M to resolve FCPA investigations
Novartis will pay nearly $347 million in combined criminal and civil penalty settlements with U.S. authorities to resolve all FCPA investigations into historical conduct by the company and its subsidiaries.
-
WebcastFeb 19 | The State of Third-Party Risk Assessments 2026
In this Compliance Week webinar, we’ll explore the most compelling findings from the report, based on independent global research conducted in collaboration with the Ponemon Institute and informed by responses from more than 1,400 third-party risk leaders and practitioners.
-
ArticleExperts warn of increased global AML risks as criminals seek to launder Venezuelan money
The U.S. action to remove President Nicolás Maduro of Venezuela and reopen access to the country’s oil reserves will have a significant impact on geopolitics and organized crime activities – creating new challenges for global compliance teams.